Search

Your search keyword '"Boos, Joachim"' showing total 310 results
Start Over Author "Boos, Joachim" Language english
310 results on '"Boos, Joachim"'

2. Four Additional Doses of PEG-L-Asparaginase During the Consolidation Phase in the AIEOP-BFM ALL 2009 Protocol Do Not Improve Outcome and Increase Toxicity in High-Risk ALL: Results of a Randomized Study.

Author

Conter, Valentino, Valsecchi, Maria Grazia, Cario, Gunnar, Zimmermann, Martin, Attarbaschi, Andishe, Stary, Jan, Niggli, Felix, Dalla Pozza, Luciano, Elitzur, Sarah, Silvestri, Daniela, Locatelli, Franco, Möricke, Anja, Engstler, Gernot, Smisek, Petr, Bodmer, Nicole, Barbaric, Draga, Izraeli, Shai, Rizzari, Carmelo, Boos, Joachim, and Buldini, Barbara

Published
2024
Full Text
View/download PDF

3. Reduced vs. standard dose native E. coli-asparaginase therapy in childhood acute lymphoblastic leukemia: long-term results of the randomized trial Moscow–Berlin 2002

Author

Karachunskiy, Alexander, Tallen, Gesche, Roumiantseva, Julia, Lagoiko, Svetlana, Chervova, Almira, von Stackelberg, Arend, Aleinikova, Olga, Bydanov, Oleg, Bajdun, Lyudmila, Nasedkina, Tatiana, Korepanova, Natalia, Kuznetsov, Sergei, Novichkova, Galina, Goroshkova, Marina, Litvinov, Dmitry, Myakova, Natalia, Ponomareva, Natalia, Inyushkina, Evgeniya, Kondratchik, Konstantin, Abugova, Julia, Fechina, Larisa, Arakaev, Oleg, Karelin, Alexander, Lebedev, Vladimir, Judina, Natalia, Scharapova, Gusel, Spichak, Irina, Shamardina, Anastasia, Ryskal, Olga, Shapochnik, Alexander, Rumjanzew, Alexander, Boos, Joachim, Henze, Günter, and for the ALL-MB study group

Published
2019
Full Text
View/download PDF

6. Therapeutic Drug Monitoring of Asparaginase: Intra-individual Variability and Predictivity in Children With Acute Lymphoblastic Leukemia Treated With PEG-Asparaginase in the AIEOP-BFM Acute Lymphoblastic Leukemia 2009 Study

Author

Würthwein, Gudrun, Lanvers-Kaminsky, Claudia, Gerss, Joachim, Möricke, Anja, Zimmermann, Martin, Stary, Jan, Smisek, Petr, Attarbaschi, Andishe, Nath, Christa, Zucchetti, Massimo, Rizzari, Carmelo, Schrappe, Martin, and Boos, Joachim

Published
2020
Full Text
View/download PDF

7. Bioanalysis of doxorubicin aglycone metabolites in human plasma samples–implications for doxorubicin drug monitoring

Author

Siebel, Christian, Lanvers‑Kaminsky, Claudia, Würthwein, Gudrun, Hempel, Georg, Boos, Joachim, and Universitäts- und Landesbibliothek Münster

Subjects
610 Medicine and health, lcsh:R, lcsh:Medicine, Article, Plasma, Oncology, Doxorubicin, Medicine and health, Humans, Chemotherapy, lcsh:Q, ddc:610, Drug Monitoring, lcsh:Science, Chromatography, High Pressure Liquid
Abstract

The widespread clinical use of the cytostatic doxorubicin together with the induction of chronic cardiomyopathy necessitates the conduct of further pharmacokinetic trials. Novel analytical technologies suitable for point-of-care applications can facilitate drug level analyses but might be prone to interferences from structurally similar compounds. Besides the alcohol metabolite doxorubicinol, aglycone metabolites of doxorubicin might affect its determination in plasma. To evaluate their analytical relevance, a validated HPLC method for the quantification of doxorubicin, doxorubicinol and four aglycones was used. The degradation pattern of doxorubicin in plasma under long-term storage was analysed with respect to the formation of aglycone products. In addition, overall 50 clinical samples obtained within the EPOC-MS-001-Doxo trial were analysed. Substantial degradation of doxorubicin in plasma occurred within a storage period of one year, but this did not lead to the formation of aglycones. In clinical samples, 7-deoxydoxorubicinolone was the major aglycone detectable in 35/50 samples and a concentration range of 1.0–12.7 μg L^−1. If at all, the other aglycones were only determined in very low concentrations. Therefore, analytical interferences from aglycones seem to be unlikely with the exception of 7-deoxydoxorubicinolone whose concentration accounted for up to 65% of the doxorubicin concentration in the clinical samples analysed., Finanziert über die DEAL-Vereinbarung mit Wiley 2019-2022.

Published
2023

13. Impact of Additional Intensive L-Asparaginase Therapy during Consolidation Phase for High-Risk Acute Lymphoblastic Leukemia: Results of a Randomized Controlled Trial in the AIEOP-BFM ALL 2009 Protocol

Author

Conter, Valentino, Valsecchi, Maria Grazia, Cario, Gunnar, Zimmermann, Martin, Attarbaschi, Andishe, Stary, Jan, Niggli, Felix, Dalla Pozza, Luciano, Elitzur, Sarah, Silvestri, Daniela, Locatelli, Franco, Moericke, Anja, Engstler, Gernot, Smisek, Petr, Bodmer, Nicole, Barbaric, Draga, Izraeli, Shai, Rizzari, Carmelo, Boos, Joachim, Buldini, Barbara, Lanvers-Kaminsky, Claudia, Cazzaniga, Giovanni, Gruhn, Bernd, Biondi, Andrea, and Schrappe, Martin

Published
2022
Full Text
View/download PDF

14. Hypersensitivity Reactions to Native E. coli L-Asparaginase in Children with Acute Lymphoblastic Leukemia May Vary By Treatment Schedule and Type of Glucocorticoid in Induction: Results of Trial ALL-BFM 2000

Author

Möricke, Anja, Schrappe, Martin, Rizzari, Carmelo, Alten, Julia, Attarbaschi, Andishe, Beier, Rita, Biondi, Andrea, Burkhardt, Birgit, Bodmer, Nicole, Boos, Joachim, Cario, Gunnar, Conter, Valentino, Flotho, Christian, Kulozik, Andreas E., Lanvers-Kaminsky, Claudia, Mann, Georg, Niggli, Felix, Silvestri, Daniela, von Stackelberg, Arend, Stanulla, Martin, Valsecchi, Maria Grazia, and Zimmermann, Martin

Published
2022
Full Text
View/download PDF

19. Adverse events during supervised exercise interventions in pediatric oncology - a nationwide survey

Author

Gauß, Gabriele, Beller, Ronja, Boos, Joachim, Däggelmann, Julia, Stalf, Hannah, Wiskemann, Joachim, and Götte, Miriam

Subjects
Medizinische Fakultät » Universitätsklinikum Essen » Zentrum für Kinder- und Jugendmedizin » Klinik für Kinderheilkunde III, questionnaire, physical activity, childhood cancer, oncological exercise therapy, ddc:610, adverse events
Abstract

Objectives: Exercise interventions during and after treatment for pediatric cancer are associated with beneficial physical, psychological, and social effects. However, valid data about adverse events (AEs) of such interventions have rarely been evaluated. This retrospective study evaluates AEs that occurred during supervised oncological exercise programs for pediatric cancer patients and survivors. Methods: This Germany-wide study used a self-administered online survey focusing on general program characteristics and AEs retrospectively for 2019. The questionnaire included (a) basic data on the offered exercise program, (b) AEs with consequences (Grade 2–5) that occurred in 2019 during an exercise intervention, (c) number of Grade 1 AEs, (d) safety procedures as part of the exercise programs, and (e) possibility to give feedback and describe experience with AEs in free text. Results: Out of 26 eligible exercise programs, response rate of program leaders was 92.3% ( n = 24). Representatives working for Universities ( n = 6), rehabilitation clinics ( n = 3), acute cancer clinics ( n = 12), and activity camps ( n = 3) participated. In total, 35,110 exercise interventions with varying duration were recorded for 2019. Six AEs with consequences (Grade 2–3) occurred during exercise interventions after cancer treatment resulting in an incidence of 17 per 100,000 exercise interventions (0.017%). No life-threatening consequences or death were reported and no serious AE occurred during acute cancer treatment. Grade 1 AE occurred with a frequency of 983, corresponding to an incidence of 2,800 per 100,000 interventions (2.8%). Most frequent Grade 1 AE were muscle soreness, circulatory problems, and abdominal pain. The most frequent preventive safety procedures at the institutions were regular breaks, consultations with the medical treatment team, and material selection with low injury potential. Conclusions: Supervised exercise interventions for pediatric cancer patients and survivors seem to be safe and AEs with consequences comparatively rare when compared to general childhood population data. Occurrence of grade 1 AEs was common, however, causality was probably not evident between AEs and the exercise intervention. Future research should standardize assessment of AEs in clinical practice and research, and prospectively register and evaluate AEs that occur in the context of exercise interventions in pediatric cancer patients and survivors.

Published
2021

32. Age and DNA-methylation subgroup as potential independent risk factors for treatment stratification in children with Atypical Teratoid/Rhabdoid Tumors

Author

Frühwald, Michael C, Hasselblatt, Martin, Nemes, Karolina, Bens, Susanne, Steinbügl, Mona, Johann, Pascal D, Kerl, Kornelius, Hauser, Peter, Quiroga, Eduardo, Solano-Paez, Palma, Biassoni, Veronica, Gil-da-Costa, Maria Joao, Perek-Polnik, Martha, van de Wetering, Marianne, Sumerauer, David, Pears, Jane, Stabell, Niklas, Holm, Stefan, Hengartner, Heinz, Gerber, Nicolas U, Grotzer, Michael, Boos, Joachim, Ebinger, Martin, Tippelt, Stefan, Paulus, Werner, Furtwängler, Rhoikos, Hernáiz-Driever, Pablo, Reinhard, Harald, Rutkowski, Stefan, Schlegel, Paul-Gerhardt, et al, and University of Zurich

Subjects
2728 Neurology (clinical), 10036 Medical Clinic, 610 Medicine & health, 2730 Oncology, 1306 Cancer Research
Published
2020

Catalog

Books, media, physical & digital resources
See catalog results